The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer
2013 · Scientific Reports · 119 citations
https://doi.org/10.1038/srep02469
S
Sílvia Cufí
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
70
Papers
4.6K
Citations
42
h-index
54
i10-index
Sílvia Cufí is an academic researcher from Institut d'Investigació Biomèdica de Girona. The author has contributed to research in topics: Metabolism, Diabetes, and Cancer & Cancer Cells and Metastasis & Cancer, Hypoxia, and Metabolism. The author has an h-index of 42, co-authored 60 publications.
ORCID: 0000-0002-2476-748XPapers by this author
worksA novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines
2011 · Breast Cancer Research · 94 citations
https://doi.org/10.1186/bcr3077
Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo
2013 · Scientific Reports · 75 citations
https://doi.org/10.1038/srep02459
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment
2012 · Oncotarget · 75 citations
https://doi.org/10.18632/oncotarget.742
Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells
2012 · British Journal of Cancer · 59 citations
https://doi.org/10.1038/bjc.2012.103
Basal/HER2 breast carcinomas
2013 · Cell Cycle · 53 citations
https://doi.org/10.4161/cc.23274
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat